Details of Disease

General Information of Disease (ID: DIS9P8YS)

Disease Name Patent ductus arteriosus
Synonyms patent ductus arteriosus familial (type); ductus arteriosus, patent; patency of the ductus arteriosus; persistent patency of the arterial duct; PDA; patent ductus arteriosus; patent ductus botalli
Definition
A congenital defect characterized by the failure of the ductus arteriosus to close soon after birth. As a consequence, blood from the aorta mixes with blood from the pulmonary artery. If untreated, it may lead to congestive heart failure.
Disease Hierarchy
DISMT2VZ: Cardiogenetic disease
DISVS67S: Vascular disease
DISQBA23: Congenital heart disease
DIS9P8YS: Patent ductus arteriosus
Disease Identifiers
MONDO ID
MONDO_0011827
MESH ID
D004374
UMLS CUI
C0013274
MedGen ID
4415
HPO ID
HP:0001643
Orphanet ID
706
SNOMED CT ID
83330001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Ibuprofen DM8VCBE Approved Small molecular drug [1]
Indomethacin DMSC4A7 Approved Small molecular drug [2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 33 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CHST15 TTFK7E1 Limited Altered Expression [3]
GSK3A TTQWAU1 Limited Biomarker [4]
ITCH TT5SEWD Limited Biomarker [5]
KCNA2 TTVFB0O Limited Biomarker [6]
KDM5A TTIG67W Limited Altered Expression [7]
MUC1 TTBHFYQ Limited Altered Expression [8]
OPRD1 TT27RFC Limited Biomarker [9]
PTGIR TTOFYT1 Limited Biomarker [10]
SMPD2 TTE5VI6 Limited Biomarker [11]
SSRP1 TTETDKQ Limited Altered Expression [12]
TRPM3 TTO3TD8 Limited Biomarker [13]
CRY1 TT5MLZR moderate Biomarker [14]
CRY2 TTAO58M moderate Biomarker [14]
CSK TTX6F0Q moderate Genetic Variation [15]
CSNK1E TTA8PLI moderate Biomarker [14]
NEK2 TT3VZ24 moderate Biomarker [16]
ABCC9 TTEF5MJ Strong Genetic Variation [17]
AGTR1 TT8DBY3 Strong Altered Expression [18]
ANXA2 TT4YANI Strong Biomarker [19]
BRCA2 TTUARD6 Strong Genetic Variation [20]
COL6A3 TT5WCAH Strong Altered Expression [21]
FOXC1 TTNT3YA Strong Altered Expression [22]
GATA4 TT1VDN2 Strong Genetic Variation [23]
KYNU TTWQM3J Strong CausalMutation [24]
MAP3K7 TTJQT60 Strong Altered Expression [25]
MSLN TT4RXME Strong Biomarker [26]
NSD1 TTTSJ3H Strong Altered Expression [27]
PDX1 TT8SGZK Strong Biomarker [28]
PTGIS TTLXKZR Strong Biomarker [29]
RAC1 TT2M9CG Strong Altered Expression [30]
SETD2 TTPC3H4 Strong Altered Expression [27]
SLC8A1 TTCF82X Strong Biomarker [31]
WT1 TTZ8UT4 Strong Biomarker [32]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC24A4 DTQWF14 Limited Altered Expression [33]
SLC45A2 DTNCJAT Limited Biomarker [34]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYP4F2 DE3GT9C moderate Altered Expression [35]
EGLN3 DEMQTKH moderate Posttranslational Modification [36]
G6PC3 DEE1B8O Strong Genetic Variation [37]
------------------------------------------------------------------------------------
This Disease Is Related to 51 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACTC1 OTJU04B1 Limited Genetic Variation [38]
ARSD OTAHW9M8 Limited Biomarker [38]
ART3 OT68OFVT Limited Biomarker [39]
CRYBG1 OTIPDI15 Limited Biomarker [34]
DYM OTQ670WI Limited Biomarker [40]
FAM83H OTN0SF11 Limited Altered Expression [41]
GATA6 OTO2BC0F Limited CausalMutation [42]
ICMT OT8CNKBO Limited Biomarker [43]
MATR3 OTESJ5S7 Limited Biomarker [44]
MPC1 OT6DYFUO Limited Altered Expression [7]
MSX2 OT1WDKE1 Limited Biomarker [45]
NTNG1 OTF48IID Limited Biomarker [46]
PALD1 OTLGUM8H Limited Biomarker [47]
PALLD OTZ2MUJZ Limited Biomarker [47]
PLAC8 OT3SYRUJ Limited Biomarker [48]
PRSS2 OTOMVUWL Limited Biomarker [49]
RASAL2 OTGMMX6W Limited Biomarker [50]
SEMA3D OTD5TJV1 Limited Biomarker [51]
SMOC1 OTJG2JQY Limited Biomarker [52]
STPG4 OT5K4UFL Limited Biomarker [53]
SUFU OT0IRYG1 Limited Biomarker [5]
TRIM29 OT2DNESG Limited Biomarker [54]
EIF4A1 OTMTBX6N Disputed Biomarker [55]
EIF4A2 OT08H03R Disputed Biomarker [55]
KRT10 OTSVRD3Q Disputed Biomarker [56]
LHX2 OTK61NP8 moderate Altered Expression [57]
LMO1 OTB59SKB moderate Altered Expression [57]
PRDM6 OTKY12D9 moderate Genetic Variation [58]
QSOX1 OT4ZPK4P moderate Altered Expression [59]
RAB2A OT6SK83U moderate Biomarker [57]
STIL OT9799VN moderate Biomarker [60]
TIPIN OT9PZHXV moderate Biomarker [14]
TRAF1 OTTLM5RU moderate Biomarker [29]
ACTA2 OTEDLG8E Strong Genetic Variation [61]
ACTB OT1MCP2F Strong Biomarker [38]
ARHGAP26 OTNGQU7A Strong Biomarker [62]
ATP5F1D OTXTAG2V Strong CausalMutation [63]
BPTF OTD1RZAD Strong CausalMutation [64]
BRCA1 OT5BN6VH Strong Altered Expression [65]
CPEB4 OTW1SCZW Strong Biomarker [66]
FOXA1 OTEBY0TD Strong Altered Expression [67]
MYH11 OTVNVWY3 Strong Genetic Variation [68]
NKX2-5 OTS1SAWM Strong Genetic Variation [23]
NPPA OTMQNTNX Strong Biomarker [69]
NRDC OTWBBCXO Strong Biomarker [70]
PTF1A OT7SWA57 Strong Genetic Variation [30]
SEL1L OTC0FB7T Strong Altered Expression [71]
SMAD4 OTWQWCKG Strong Genetic Variation [72]
TBX5 OT70PISV Strong Genetic Variation [23]
TP63 OT0WOOKQ Strong Biomarker [73]
PDHX OTG7O271 Definitive Biomarker [28]
------------------------------------------------------------------------------------
⏷ Show the Full List of 51 DOT(s)

References

1 Ibuprofen FDA Label
2 Indomethacin FDA Label
3 Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma.Oncol Lett. 2017 Jun;13(6):4799-4805. doi: 10.3892/ol.2017.6071. Epub 2017 Apr 21.
4 Differential activity of GSK-3 isoforms regulates NF-B and TRAIL- or TNF induced apoptosis in pancreatic cancer cells.Cell Death Dis. 2014 Mar 27;5(3):e1142. doi: 10.1038/cddis.2014.102.
5 Lithium Suppresses Hedgehog Signaling via Promoting ITCH E3 Ligase Activity and Gli1-SUFU Interaction in PDA Cells.Front Pharmacol. 2017 Nov 16;8:820. doi: 10.3389/fphar.2017.00820. eCollection 2017.
6 Patterns of gene expression in the ductus arteriosus are related to environmental and genetic risk factors for persistent ductus patency.Pediatr Res. 2010 Oct;68(4):292-7. doi: 10.1203/PDR.0b013e3181ed8609.
7 A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism.Oncogene. 2020 Jan;39(5):1140-1151. doi: 10.1038/s41388-019-1051-8. Epub 2019 Oct 22.
8 Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.Front Oncol. 2019 Apr 30;9:330. doi: 10.3389/fonc.2019.00330. eCollection 2019.
9 Effects of Prenatal PM(10) Exposure on Fetal Cardiovascular Malformations in Fuzhou, China: A Retrospective Case-Control Study.Environ Health Perspect. 2017 May 25;125(5):057001. doi: 10.1289/EHP289.
10 Expression of prostanoid receptors in human ductus arteriosus.Br J Pharmacol. 2003 Feb;138(4):655-9. doi: 10.1038/sj.bjp.0705092.
11 Ceramide mediates acute oxygen sensing in vascular tissues.Antioxid Redox Signal. 2014 Jan 1;20(1):1-14. doi: 10.1089/ars.2012.4752. Epub 2013 Aug 21.
12 SOX9 inhibits -TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties.J Cell Sci. 2015 Mar 15;128(6):1123-38. doi: 10.1242/jcs.162164. Epub 2015 Jan 27.
13 Decreased serum osmolality promotes ductus arteriosus constriction.Cardiovasc Res. 2014 Nov 1;104(2):326-36. doi: 10.1093/cvr/cvu199. Epub 2014 Sep 4.
14 Circadian gene expression and clinicopathologic correlates in pancreatic cancer.J Gastrointest Surg. 2013 Mar;17(3):443-50. doi: 10.1007/s11605-012-2112-2. Epub 2012 Dec 20.
15 Oncogenic Ras/Src cooperativity in pancreatic neoplasia.Oncogene. 2011 May 5;30(18):2123-34. doi: 10.1038/onc.2010.589. Epub 2011 Jan 17.
16 Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2462-9. eCollection 2014.
17 A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders.Genet Med. 2016 Nov;18(11):1090-1096. doi: 10.1038/gim.2016.1. Epub 2016 Mar 3.
18 Identification of differentially regulated genes in human patent ductus arteriosus.Exp Biol Med (Maywood). 2016 Dec;241(18):2112-2118. doi: 10.1177/1535370216661778. Epub 2016 Jul 28.
19 Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2.Cell Adh Migr. 2017 Sep 3;11(5-6):514-523. doi: 10.1080/19336918.2016.1259057. Epub 2017 Feb 6.
20 Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response.Clin Cancer Res. 2020 Mar 15;26(6):1297-1308. doi: 10.1158/1078-0432.CCR-18-3669. Epub 2019 Dec 12.
21 Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.J Gastrointest Surg. 2014 Jan;18(1):7-15. doi: 10.1007/s11605-013-2326-y. Epub 2013 Sep 4.
22 High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.Tumour Biol. 2013 Apr;34(2):853-8. doi: 10.1007/s13277-012-0617-7. Epub 2012 Dec 16.
23 Association of NKX2-5, GATA4, and TBX5 polymorphisms with congenital heart disease in Egyptian children.Mol Genet Genomic Med. 2019 May;7(5):e612. doi: 10.1002/mgg3.612. Epub 2019 Mar 4.
24 NAD Deficiency, Congenital Malformations, and Niacin Supplementation. N Engl J Med. 2017 Aug 10;377(6):544-552.
25 MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-B Pathway In Vitro.Dig Dis Sci. 2017 Apr;62(4):944-957. doi: 10.1007/s10620-017-4472-7. Epub 2017 Feb 13.
26 Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.Cancer Immunol Res. 2019 Jun;7(6):977-989. doi: 10.1158/2326-6066.CIR-18-0448. Epub 2019 Apr 26.
27 Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions.Pathology. 2019 Jun;51(4):392-398. doi: 10.1016/j.pathol.2019.02.005. Epub 2019 May 3.
28 RET, a targetable driver of pancreatic adenocarcinoma.Int J Cancer. 2019 Jun 15;144(12):3014-3022. doi: 10.1002/ijc.32040. Epub 2019 Jan 11.
29 Determination of genetic predisposition to patent ductus arteriosus in preterm infants.Pediatrics. 2009 Apr;123(4):1116-23. doi: 10.1542/peds.2008-0313.
30 PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.Gastroenterology. 2014 Dec;147(6):1405-16.e7. doi: 10.1053/j.gastro.2014.08.032. Epub 2014 Aug 27.
31 The Role of Na+/Ca2+ Exchanger 1 in Maintaining Ductus Arteriosus Patency.Sci Rep. 2017 Aug 29;7(1):9826. doi: 10.1038/s41598-017-10377-z.
32 Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.Oncology. 2019;97(3):135-148. doi: 10.1159/000500359. Epub 2019 Jun 19.
33 Elevated NCX1 and NCKX4 expression in the patent postnatal ductus arteriosus of ductal-dependent congenital heart disease patients.Pediatr Cardiol. 2015 Apr;36(4):743-51. doi: 10.1007/s00246-014-1070-8. Epub 2014 Dec 12.
34 Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation.BMC Pediatr. 2019 Sep 13;19(1):333. doi: 10.1186/s12887-019-1708-z.
35 Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcinoma.Ann Surg Oncol. 2013 Dec;20 Suppl 3:S636-43. doi: 10.1245/s10434-013-3128-x. Epub 2013 Jul 12.
36 Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition.PLoS One. 2013 Dec 18;8(12):e83021. doi: 10.1371/journal.pone.0083021. eCollection 2013.
37 Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3.Eur J Hum Genet. 2011 Jan;19(1):18-22. doi: 10.1038/ejhg.2010.136. Epub 2010 Aug 18.
38 Congenital heart defects are rarely caused by mutations in cardiac and smooth muscle actin genes.Biomed Res Int. 2015;2015:127807. doi: 10.1155/2015/127807. Epub 2015 Mar 10.
39 Antenatal Administration of Betamethasone Contributes to Intimal Thickening of the Rat Ductus Arteriosus.Circ J. 2019 Feb 25;83(3):654-661. doi: 10.1253/circj.CJ-18-1033. Epub 2019 Feb 7.
40 Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus.Circulation. 2004 Sep 14;110(11):1372-9. doi: 10.1161/01.CIR.0000141292.28616.65. Epub 2004 Sep 7.
41 Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma.Gut. 2019 Mar;68(3):499-511. doi: 10.1136/gutjnl-2017-314353. Epub 2018 Feb 10.
42 Whole exome sequencing identifies de novo mutations in GATA6 associated with congenital diaphragmatic hernia.J Med Genet. 2014 Mar;51(3):197-202. doi: 10.1136/jmedgenet-2013-101989. Epub 2014 Jan 2.
43 Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.J Clin Invest. 2013 Nov;123(11):4681-94. doi: 10.1172/JCI65764.
44 MATR3 disruption in human and mouse associated with bicuspid aortic valve, aortic coarctation and patent ductus arteriosus.Hum Mol Genet. 2015 Apr 15;24(8):2375-89. doi: 10.1093/hmg/ddv004. Epub 2015 Jan 7.
45 Results of the combined U.S. multicenter postapproval study of the Nit-Occlud PDA device for percutaneous closure of patent ductus arteriosus.Catheter Cardiovasc Interv. 2019 Mar 1;93(4):645-651. doi: 10.1002/ccd.27995. Epub 2018 Dec 3.
46 Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling.Cell Death Dis. 2015 Jan 15;6(1):e1592. doi: 10.1038/cddis.2014.557.
47 Isoform-specific upregulation of palladin in human and murine pancreas tumors.PLoS One. 2010 Apr 26;5(4):e10347. doi: 10.1371/journal.pone.0010347.
48 Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression.Cell Rep. 2014 May 22;7(4):1143-55. doi: 10.1016/j.celrep.2014.03.061. Epub 2014 May 1.
49 Altered plasma proteins released from platelets and endothelial cells are associated with human patent ductus arteriosus.J Cell Physiol. 2019 May;234(5):6842-6853. doi: 10.1002/jcp.27433. Epub 2018 Nov 27.
50 Sulforaphane Induces miR135b-5p and Its Target Gene, RASAL2, thereby Inhibiting the Progression of Pancreatic Cancer.Mol Ther Oncolytics. 2019 Apr 6;14:74-81. doi: 10.1016/j.omto.2019.03.011. eCollection 2019 Sep 27.
51 Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer.Sci Signal. 2015 Aug 4;8(388):ra77. doi: 10.1126/scisignal.aaa5823.
52 Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.Virology. 2013 Feb 5;436(1):221-34. doi: 10.1016/j.virol.2012.11.014. Epub 2012 Dec 14.
53 Transcriptional profiles in the chicken ductus arteriosus during hatching.PLoS One. 2019 Mar 21;14(3):e0214139. doi: 10.1371/journal.pone.0214139. eCollection 2019.
54 ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.Genes Dev. 2019 Jun 1;33(11-12):641-655. doi: 10.1101/gad.323303.118. Epub 2019 May 2.
55 eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma.Nat Commun. 2019 Nov 13;10(1):5151. doi: 10.1038/s41467-019-13086-5.
56 Modeling Human Cancer-induced Cachexia.Cell Rep. 2019 Aug 6;28(6):1612-1622.e4. doi: 10.1016/j.celrep.2019.07.016.
57 Oncogenicity of LHX2 in pancreatic ductal adenocarcinoma.Mol Biol Rep. 2014 Dec;41(12):8163-7. doi: 10.1007/s11033-014-3716-2. Epub 2014 Oct 17.
58 Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus. Am J Hum Genet. 2016 Jun 2;98(6):1082-1091. doi: 10.1016/j.ajhg.2016.03.022. Epub 2016 May 12.
59 Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases.Mol Cancer Res. 2011 Dec;9(12):1621-31. doi: 10.1158/1541-7786.MCR-11-0018. Epub 2011 Oct 11.
60 SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cell.Cancer Res. 2008 Oct 1;68(19):7723-9. doi: 10.1158/0008-5472.CAN-07-6661.
61 Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations. Genet Med. 2018 Oct;20(10):1206-1215. doi: 10.1038/gim.2017.245. Epub 2018 Jan 4.
62 Hypoxia-induced ARHGAP26 deficiency inhibits the proliferation and migration of human ductus arteriosus smooth muscle cell through activating RhoA-ROCK-PTEN pathway.J Cell Biochem. 2019 Jun;120(6):10106-10117. doi: 10.1002/jcb.28294. Epub 2018 Dec 28.
63 Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder. Am J Hum Genet. 2018 Mar 1;102(3):494-504. doi: 10.1016/j.ajhg.2018.01.020. Epub 2018 Feb 22.
64 Haploinsufficiency of the Chromatin Remodeler BPTF Causes Syndromic Developmental and Speech Delay, Postnatal Microcephaly, and Dysmorphic Features. Am J Hum Genet. 2017 Oct 5;101(4):503-515. doi: 10.1016/j.ajhg.2017.08.014. Epub 2017 Sep 21.
65 BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells.J Clin Endocrinol Metab. 2006 Nov;91(11):4514-9. doi: 10.1210/jc.2006-1364. Epub 2006 Aug 29.
66 Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma.PLoS One. 2016 May 9;11(5):e0155025. doi: 10.1371/journal.pone.0155025. eCollection 2016.
67 Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.Cell. 2017 Aug 24;170(5):875-888.e20. doi: 10.1016/j.cell.2017.07.007. Epub 2017 Jul 27.
68 Utilization of Whole Exome Sequencing to Identify Causative Mutations in Familial Congenital Heart Disease.Circ Cardiovasc Genet. 2016 Aug;9(4):320-9. doi: 10.1161/CIRCGENETICS.115.001324. Epub 2016 Jul 14.
69 Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus. Acta Paediatr. 1992 Sep;81(9):672-5. doi: 10.1111/j.1651-2227.1992.tb12330.x.
70 Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice.Gut. 2019 May;68(5):882-892. doi: 10.1136/gutjnl-2017-315425. Epub 2018 May 24.
71 Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.Mol Carcinog. 2014 Sep;53(9):711-21. doi: 10.1002/mc.22023. Epub 2013 May 9.
72 Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.Br J Cancer. 2017 Aug 8;117(4):572-582. doi: 10.1038/bjc.2017.209. Epub 2017 Jul 18.
73 TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.Cell Rep. 2018 Nov 13;25(7):1741-1755.e7. doi: 10.1016/j.celrep.2018.10.051.